Skip to content
RNAWiki

Rucaparib

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Rucaparib does in the body

RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes. Rucaparib has been shown to decrease tumor growth in mouse xenograft models of human cancer with or without deficiencies in BRCA .

Why people take it. RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 41AX9SJ8KO · read 2026-08-29

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 202 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Protein

A protein is a folded chain your body builds to do a specific job.

A picture of it, and where the picture fails

A protein is like a tool bent into one shape for one task.

Where that stops being true. A tool keeps its shape. A protein can change shape and stop working.

What people get wrong. Protein in food and a protein in the body are related but not the same thing.

A polymer of amino acids folded into a defined structure that determines its function.

Enzyme

An enzyme is a protein that speeds up one chemical change.

A picture of it, and where the picture fails

An enzyme is like a machine on a production line doing one cut.

Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.

What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.

A catalytic protein that lowers the activation energy of a specific reaction.

Receptor

A receptor is a part of a cell that a signal fits into.

A picture of it, and where the picture fails

A receptor is like a lock waiting for one key.

Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.

What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.

A protein that binds a specific ligand and converts that binding into a cellular response.

Pathway

A pathway is a chain of steps inside a cell, each one setting off the next.

A picture of it, and where the picture fails

A pathway is like a row of dominoes.

Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.

What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.

An ordered series of molecular interactions producing a defined cellular change.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Percentage of patients that are treated based on their molecular tumor profile

The study did not show it

Who was studied
NCT02925234
How many people
1550
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • ClinicalTrials.gov · a recorded source, not a stored snapshot

Incidence of Adverse Events (AEs)

The study did not show it

Who was studied
NCT03899155
How many people
1500
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • ClinicalTrials.gov · a recorded source, not a stored snapshot

Monotherapy Arm B and Arm D: Investigator Assessed Progression-free Survival (PFS)

The study did not show it

Who was studied
NCT03522246
How many people
1097
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • ClinicalTrials.gov · a recorded source, not a stored snapshot

Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)

The study did not show it

Who was studied
NCT03768063
How many people
1000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • ClinicalTrials.gov · a recorded source, not a stored snapshot

Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)

The study did not show it

Who was studied
NCT01968213
How many people
564
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • ClinicalTrials.gov · a recorded source, not a stored snapshot

Progression Free Survival (PFS)

The study did not show it

Who was studied
NCT02678182
How many people
494
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route.

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • Europe PMC · a recorded source, not a stored snapshot
  • ClinicalTrials.gov · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What happened in peopleRead from sources, not yet reviewed

How close this is to real life

The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.

  1. Living longer, or avoiding a major event Evidence recorded. Death, a heart attack, a stroke, a hospital stay.7 registered measures of this kind. 3 written-up studies measured this and did not show a benefit.
  2. What a body can do day to day No evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
  3. Measured performance No evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
  4. Symptoms and quality of life No evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
  5. A number that stands in for health No evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.No registered study measures this.
  6. A step measured inside a person Evidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
  7. Animals Evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
  8. Cells in a dish Evidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
  9. A guess from software No evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.

Higher on these steps means closer to something a person would feel. It does not mean better done.

What it would be like to takeRead from sources, not yet reviewed

Felt, measured, or meaningful

Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.

Felt

Things a person could notice without a test.

No registered study measured anything of this kind.

Measured

Things only a test, a scale or a device shows.

No registered study measured anything of this kind.

Meaningful

Things that change how a life goes, not only a number.

  • progression free survival
  • progression free survival at 6 months
  • prostate specific antigen progression free survival
  • progression free survival in months
  • incidence of death
  • radiographic progression free survival
  • overall survival

A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.

Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.

Measured, but not felt. A number moves. The person notices nothing. Both can be true.

Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.

Matters, but takes years. The result that counts may take longer than anyone would keep watching.

Names that fit none of the three (30)
  • safety profile
  • dose limiting toxicity
  • clinical benefit rate
  • treatment emergent adverse events
  • cohort 1 objective response rate
  • cohort 2 objective response rate
  • cohort 3 tolerability
  • that are treated based on their molecular tumor profile
  • objective tumor response
  • stable disease
  • treatment related grade 3 and serious adverse events
  • duration of response
  • adverse events
  • dose limiting toxicities
  • dose modifications due to adverse events
  • overall response rate
  • prostate specific antigen response rate
  • treatment related overall response rate
  • prostate specific antigen response
  • incidence of adverse events

These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

No description of who was studied is recorded.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness of Rubraca in pediatric patients have not been established.”

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

  • On older people, the label states: “Of the 937 patients with ovarian cancer who received Rubraca in clinical trials including ARIEL3, 41% were age 65 or older and 10% were 75 years or older.”

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women.”

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of rucaparib in human milk, or on its effects on milk production or the breast-fed child.”

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

  • On people with reduced liver function, the label states: “No dosage modification is recommended for patients with mild to moderate hepatic impairment (total bilirubin ≤ 3 x upper limit of normal [ULN] or AST > ULN) [see Clinical Pharmacology ( 12.3 )] .”

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

  • On people with reduced kidney function, the label states: “No dosage modification is recommended for patients with mild to moderate renal impairment (creatinine clearance [CLcr] between 30 and 89 mL/min, as estimated by the Cockcroft-Gault method) [see Clinical Pharmacology ( 12.3 )].”

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied for a different goal

The studies measured something else entirely.

On this record: Some registered studies measured things that match no goal on this page.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No form or route is recorded.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S1, S3, S4.

No source is stored against this line.

What is in the pack

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing is recorded about product quality.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Reports sent to a regulator

  • These are reports people sent to a regulator. They do not show the medicine caused the reaction.
  • Nobody counted how many people took the medicine and reported nothing.
  • The same event can be reported more than once, and many reports are incomplete.
  • News coverage, lawsuits and new warnings change how often people report.
  • A count is not a rate and not a risk.

Rucaparib appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 6467 reaction mentions were counted. One report can name several reactions.

The recorded terms (10)
  • fatigue — 1557 reaction mentions
  • nausea — 1415 reaction mentions
  • malignant neoplasm progression — 664 reaction mentions
  • decreased appetite — 481 reaction mentions
  • constipation — 454 reaction mentions
  • vomiting — 442 reaction mentions
  • diarrhoea — 410 reaction mentions
  • dysgeusia — 375 reaction mentions
  • asthenia — 339 reaction mentions
  • anaemia — 330 reaction mentions
  • open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

The exact form studied is not recorded.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-29

  • Rubraca is oral at 3 DOSAGE FORMS AND STRENGTHS Tablets (200 mg): blue, round, immediate-release, film-coated, debossed with “C2”., recorded as fda label in effect 2025-12-31 in the United States.

    US prescribing information · 0295d202-1cfe-7659-e063-6294a90a476e · read 2026-08-30

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Rucaparib studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

How much did people take in the studies?

The sources RNAWiki checked hold nothing for this field.

Why it matters. A result belongs to an amount. Without the amount the result floats free.

What would answer it

A stored source that records it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Rucaparib are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
41AX9SJ8KO
RxNorm concept
1862584

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S1, S3, S4.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

8 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • How this medicine reached us — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (11)

What did Rucaparib's largest trial (1550 people) and its longest (13 years) measure?

1550 people in Rucaparib's largest registered study, 13 years in its longest registered window, measuring PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data. ClinicalTrials.gov · 2026-09-01

39 phase2, 23 phase1, 8 phase3, 1 early phase1, 1 na or unstated; NCT03522246; 2030-12-30; no ageing endpoint recorded. Last human test completed 2026, NCT03694262.

Interpretation These counts include studies where Rucaparib was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.

Show the evidence
  • phase2
    39
  • phase1
    23
  • phase3
    8
  • early phase1
    1
  • na or unstated
    1
  • Last recorded human test NCT03694262
    2026-03-10

recorded 2026-09-01 · last checked 2026-09-04

From mouse to human: where has Rucaparib shown biomarker?

mouse: mechanism-only and human: biomarker (61): the rungs where Rucaparib has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01

Interpretation PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma… — the recorded outcome words.

Yeast C. elegans Drosophila Mouse mechanism-onlyRat Dog Non-human primate Human biomarker
Show the evidence
  • mouse
    mechanism-only
  • human NCT02740712
    biomarker; PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin with and without rucaparib treatment to be calculated from the plasma concentration-time data; 61

recorded 2026-09-01 · last checked 2026-09-04

13 of Rucaparib's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?

safety (1), futility/efficacy (2), accrual/recruitment (1), funding/business (5) and other (4): Rucaparib's stop wording, clustered. ClinicalTrials.gov · 2026-09-01

"Study terminated due to safety issues."; 13 of 61 registered studies

Show the evidence

Trial

  • NCT02711137
    terminated; "Study terminated due to safety issues."
  • NCT03140670
    terminated; "Loss of funding"
  • NCT03397394
    terminated; "Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment."
  • NCT03442556
    terminated; "Terminated due to insufficient funding"
  • NCT03533946
    terminated; "New standard of care for study participant population"
  • NCT03559049
    terminated; "Due to financial hardships suffered by the stakeholder"
7 further recorded trials
  • NCT03572478
    terminated; "The study was terminated due to lack of efficacy."
  • NCT03795272
    withdrawn; "Lack of financial support"
  • NCT03824704
    terminated; "Sponsor made a business decision to discontinue the study due to low accrual."
  • NCT03992131
    terminated; "Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time."
  • NCT04171700
    terminated; "The study was terminated due to a change in development priorities."
  • NCT04276376
    terminated; "Bankruptcy of partner: Clovis"
  • NCT04826198
    terminated; "Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired."

recorded 2026-09-01 · last checked 2026-09-04

Which of adverse events, best objective response rate and clinical benefit rate did Rucaparib's trials measure?

adverse events, best objective response rate and clinical benefit rate lead 37 outcome terms across Rucaparib's trials. ClinicalTrials.gov · 2026-09-01

progression free survival, treatment emergent adverse events, cohort 1 objective response rate, cohort 2 objective response rate, cohort 3 tolerability and that are treated based on their molecular tumor profile follow.

Show the evidence
  • safety profile
    1
  • dose limiting toxicity
    1
  • clinical benefit rate
    1
  • progression free survival
    1
  • treatment emergent adverse events
    1
  • cohort 1 objective response rate
    1
14 more recorded rows
  • cohort 2 objective response rate
    1
  • cohort 3 tolerability
    1
  • that are treated based on their molecular tumor profile
    1
  • objective tumor response
    1
  • stable disease
    1
  • treatment related grade 3 and serious adverse events
    1
  • duration of response
    1
  • adverse events
    1
  • dose limiting toxicities
    1
  • dose modifications due to adverse events
    1
  • progression free survival at 6 months
    1
  • overall response rate
    1
  • prostate specific antigen response rate
    1
  • prostate specific antigen progression free survival
    1

recorded 2026-09-01 · last checked 2026-09-04

Which of Rucaparib's 9 ongoing trials reports first?

9 registered trials of Rucaparib are open; earliest completion 2026-11-16. ClinicalTrials.gov · 2026-09-01

Progression Free Survival (PFS); Cohort 1: Objective Response Rate; latest 2030-12-30

Show the evidence

Trial

  • NCT02678182
    "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial"; n 494; "Progression Free Survival (PFS)"; 2027-06
  • NCT02873962
    "A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib"; n 72; "Cohort 1: Objective Response Rate"; 2027-01
  • NCT02925234
    "The Drug Rediscovery Protocol (DRUP Trial)"; n 1550; "Percentage of patients that are treated based on their molecular tumor profile"; 2027-12
  • NCT03522246
    "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy"; n 1097; "Monotherapy Arm B and Arm D: Investigator Assessed Progression-free Survival (PFS)"; 2030-12-30
  • NCT03768063
    "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study"; n 1000; "Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)"; 2028-07-05
  • NCT03899155
    "Pan Tumor Rollover Study"; n 1500; "Incidence of Adverse Events (AEs)"; 2029-08-25
3 further recorded trials
  • NCT04253262
    "A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer"; n 13; "Maximum Tolerated Dose"; 2027-01
  • NCT04455750
    "A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy"; n 61; "Radiographic progression-free survival (rPFS)"; 2027-09
  • NCT04624178
    "A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma"; n 20; "Best Objective Response Rate"; 2026-11-16

recorded 2026-09-01 · last checked 2026-09-04

Which running trial of Rucaparib could settle lifespan?

NCT02678182 measures Progression Free Survival (PFS), reading out 2027-06.

3 open trials; n 494; "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial"

Show the evidence

Trial

  • NCT02678182
    "Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial"; n 494; "Progression Free Survival (PFS)"; 2027-06
  • NCT04455750
    "A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy"; n 61; "Radiographic progression-free survival (rPFS)"; 2027-09
  • NCT03522246
    "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy"; n 1097; "Monotherapy Arm B and Arm D: Investigator Assessed Progression-free Survival (PFS)"; 2030-12-30

Which 14 trials of Rucaparib posted no result?

Posted no result
14 of 14 completed trials
Registrations
NCT01009190, NCT00664781, NCT02042378, NCT02986100, NCT02740712 and NCT02505048, and 8 more
Completion dates
oldest 2014-04; newest 2024-07-01
Show the evidence

Trial

  • NCT01009190
    2014-04
  • NCT00664781
    2015-01
  • NCT02042378
    2016-05
  • NCT02986100
    2018-09
  • NCT02740712
    2019-09
  • NCT02505048
    2019-12
8 further recorded trials
  • NCT03101280
    2020-08-11
  • NCT03521037
    2021-02-24
  • NCT03318445
    2021-03-01
  • NCT03954366
    2021-06-09
  • NCT03911453
    2021-07-16
  • NCT03499444
    2022-04-13
  • NCT03552471
    2022-12-19
  • NCT04227522
    2024-07-01

At the median, Rucaparib's trials enrolled 42 people — anything larger?

Median enrolment
42
Largest enrolment
1550
Registered trials counted
61

What do 6467 spontaneous reports say about Rucaparib — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Rucaparib appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 6467 reaction mentions were counted: fatigue 1557; nausea 1415; malignant neoplasm progression 664; decreased appetite 481. open-targets-adr · CHEMBL1173055 · 2026-06-24

Show the evidence
  • fatigue
    1557
  • nausea
    1415
  • malignant neoplasm progression
    664
  • decreased appetite
    481
  • constipation
    454
  • vomiting
    442
4 more recorded rows
  • diarrhoea
    410
  • dysgeusia
    375
  • asthenia
    339
  • anaemia
    330

recorded 2026-06-24 · last checked 2026-09-04

Rucaparib and CYP1A2, CYP2D6 and BCRP: shared by which compounds?

CYP1A2, CYP2D6 and BCRP appear in Rucaparib's recorded interaction sentences, 8 in all. openfda-label+europepmc · 2026-08-30

Interpretation pharmacokinetics

Show the evidence

CYP1A2

  • pharmacokinetics
    Metabolism In vitro, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.
  • pharmacokinetics
    Specific Populations Age (20 to 86 years), race (White, Black, and Asian), sex, body weight (41 to 171 kg), mild to moderate renal impairment (CLcr ≥ 30 mL/min), mild hepatic impairment (total bilirubin < ULN and AST > ULN or total bilirubin 1 to 1.5 x ULN and any AST), and CYP2D6 or CYP1A2 genotype polymorphisms did not have a clinically meaningful effect on the pharmacokinetics of rucaparib.
  • pharmacokinetics
    In Vitro Studies Cytochrome P450 (CYP) Enzymes : Rucaparib inhibited CYP2C8 and CYP2D6 and induced CYP1A2.
  • CYP2C8 pharmacokinetics
    In Vitro Studies Cytochrome P450 (CYP) Enzymes : Rucaparib inhibited CYP2C8 and CYP2D6 and induced CYP1A2.

CYP2D6

  • pharmacokinetics
    Metabolism In vitro, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.
  • pharmacokinetics
    Specific Populations Age (20 to 86 years), race (White, Black, and Asian), sex, body weight (41 to 171 kg), mild to moderate renal impairment (CLcr ≥ 30 mL/min), mild hepatic impairment (total bilirubin < ULN and AST > ULN or total bilirubin 1 to 1.5 x ULN and any AST), and CYP2D6 or CYP1A2 genotype polymorphisms did not have a clinically meaningful effect on the pharmacokinetics of rucaparib.
  • pharmacokinetics
    In Vitro Studies Cytochrome P450 (CYP) Enzymes : Rucaparib inhibited CYP2C8 and CYP2D6 and induced CYP1A2.
  • CYP3A4 pharmacokinetics
    Metabolism In vitro, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4.

recorded 2026-08-30 · last checked 2026-09-04

What is recorded about Rucaparib and mTOR?

"Furthermore, co-treatment with mTORC1 inhibitors enhanced the cellular effects of rucaparib in resistant cells, suggesting a therapeutic potential of targeting downstream mTOR effectors to overcome intrinsic resistance." — where Rucaparib and mTOR appear together. Europe PMC · pathway abstract search · 2026-09-02

mTOR, NAD+, autophagy, sirtuin; PMID 42685115, 41661673, 35740560, 34572083

Show the evidence
  • mTOR PMID 42685115
    "Furthermore, co-treatment with mTORC1 inhibitors enhanced the cellular effects of rucaparib in resistant cells, suggesting a therapeutic potential of targeting downstream mTOR effectors to overcome intrinsic resistance."
  • NAD+ PMID 41661673
    "Treatment with the PARP inhibitor rucaparib showed potent synergy with 5-FU and demonstrated robust tumor suppression in patient-derived organoids and xenograft models through NAD+-mediated metabolic perturbation."

autophagy

  • PMID 35740560
    "In mouse diaphragm and gastrocnemius (LP07 lung adenocarcinoma) treated with PARP inhibitor (rucaparib,150 mg/kg body weight/24 h for 20 days) and in non-tumor control animals, body, muscle, and tumor weights; tumor area; limb muscle strength; physical activity; muscle structural abnormalities, damage, and phenotype; PARP activity; and proteolytic and autophagy markers were quantified."
  • PMID 35740560
    "Treatment with the PARP inhibitor rucaparib elicited a significant improvement in body weight gain, tumor size and weight, physical activity, muscle damage, troponin I, and proteolytic and autophagy levels."
  • mTOR PMID 34572083
    "The migratory and proliferative capacity of PEO1 cells was compromised following treatment with rucaparib 10 µM compared to BRCA2 wild-type cell lines via a mechanism involving the mTOR pathway."
  • sirtuin PMID 26518726
    "We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939."
  • autophagy PMID 31714594
    "Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) induced autophagy in a panel of ovarian cancer cells."
  • NAD+ PMID 28543772
    "Proton magnetic resonance spectroscopy (<sup>1</sup> H-MRS) was used to study the impact of rucaparib in vitro and ex vivo in liver tissue from mice, via quantitative analysis of nicotinamide adenosine diphosphate (NAD<sup>+</sup> ) spectra, to assess the potential of MRS as a biomarker of the PARP inhibitor response."
  • sirtuin PMID 23301673
    "Here, we firstly demonstrate an inverse correlation between AKT acetylation and phosphorylation modulated by SIRT1 in MMe cells treated with CO-338."
  • NAD+ PMID 30880062
    "Because histone-dependent activation is unique to PARP-1, non-NAD-like PARP-1 inhibitors have the potential to bypass the off-target effects of classical NAD-dependent PARP-1 inhibitors, such as olaparib, veliparib, and rucaparib."
1 more recorded row
  • mTOR PMID 27055253
    "Using reverse-phase protein array, we found the proteins most significantly upregulated following treatment with the PARP inhibitors olaparib and rucaparib were in the PI3K/mTOR pathway (p-mTOR, p-AKT, and pS6) (p≤0.02)."

recorded 2026-09-02 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1173055
PubChem CID
9931954
CAS number
283173-50-2
RxCUI
1862579
InChIKey
HMABYWSNWIZPAG-UHFFFAOYSA-N
Development code
AG-14447, AG014699, AG-14699, PF-01367338, PF01367338, C0-338, CO-338, PF-1367338-BW
Also called
parp inhibitors, parpi, RUCAPARIB PHOSPHATE, Ag 014699, RUCAPARIB CAMSYLATE, RUCAPARIB CAMSYLATE [MI], RUCAPARIB CAMSYLATE [ORANGE BOOK], RUCAPARIB CAMSYLATE [USAN], Rucaparib camsylate [WHO-DD]
Trade name
Rubraca
Sources (10)

Sources

4 more sources
  • open-targets-adr CHEMBL1173055 ·
  • openfda-label 0295d202-1cfe-7659-e063-6294a90a476e ·
  • openfda-label+europepmc K1:8237F3U7EH ·
  • national registers US, EU ·

ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 10 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.